

## Index

### **a**

acetyl-coenzymeA (AcCoA) 24ff.  
 adenosine mimetics 228  
*S*-adenosyl-L-homocysteine (AdoHcy or SAH) 36ff., 255  
*S*-adenosyl-L-homocysteine hydrolase (SAHH) 111  
*S*-adenosyl-L-methionine (AdoMet or SAM) 36ff., 110, 163, 249  
 AdoMet-dependent methyltransferase (MTase) 36  
 ADS100380 66, 198  
 ADS102550 199  
 AGK2 68f., 229ff.  
 aliphatic hydroxamic acid 192  
   – SAR 193  
 aliphatic ketone 213  
 allantodapsone 75, 257  
 Alzheimer's disease (AD) 234  
 AMC (Ac-GA-(NH-Ac-K)-amino-4-methylcoumarin) 120  
 AMI-1 (arginine methyltransferase inhibitor 1) 255  
 AMI-5 (eosin) 75, 256  
 AMI-6 255  
 aminoaniline 200  
   – HDAC1- and HDAC2-selective 204  
   – SAR 201  
 6-aminohexanoic acid 192  
 amplified luminescent proximity homogeneous assay (AlphaScreen) 108  
 AN9 189  
 anacardic acid 243  
 androgen receptor (AR) 234, 271  
 ANOVA 146  
 antiangiogenesis 169  
 antiangiogenic assay 129  
 antibody

  – ChIP 143  
 antibody-based assay 108  
 anticancer activity 129, 243  
   – sirtuin 232ff.  
 apicidin 16, 189, 208  
 apoptosis 169  
 arginine demethylase 44, 113  
 arginine methyltransferase, *see* protein arginine methyltransferase (PRMT)  
 aristoforin 228, 246  
 ASH2/WDR5/MLL family methyltransferase complex 11  
 assay  
   – antiangiogenic 129  
   – antibody-based 108  
   – biological function-based 125ff.  
   – cell proliferation 125  
   – cell-based 119ff.  
   – fluorescent 102ff.  
   – *in vitro* 99ff., 120  
   – *in vitro* high-throughput 121  
   – *in vitro* isoform-specificity 121  
   – invasion 130  
   – radioactive 101  
 5-azacytidine (AzaC, azacitidine, vidaza) 14, 170ff.  
 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) 110  
 azumamide 211

### **b**

BCL6 233  
 belinostat 194ff.  
 benzothiophen-2-yl hydroxamic acid 199  
 BHC110, *see* lysine-specific histone demethylase (LSD1)  
 BHC80-PHD finger 10  
 binding free energy calculation 60

- biological function-based assay 125ff.
- bisindolylmaleimide (BIM) 228
- bivalent chromatin domain 140
- Bix-01294 78, 259
- Bix-01338 78, 259
- Boc(Ac)Lys-AMC (MAL) 102
- bromodomain 7f.
- bromodomain and PHD domain transcription factor (BPTF) 11
- butyric acid (BA) 188
- butyrate 15
- c**
- cambinol 70f., 228ff.
- cancer
  - sirtuin 232ff.
  - lysine methyltransferase (KMT, PKMT) 253
- capillary electrophoresis 88
- m*-carboxycinnamic acid bishydroxamide (CBHA)
- CARM1 (PRMT4) 39, 48, 75, 250ff.
- CBP (CREB-binding protein) 241
  - p300/CBP family 74, 242
- CCT077791 245
- CCT077792 245
- CD04097 68
- CDKN2A 175
- CDKN2B 175
- cell adherence 169
- cell cycle gene 169
- cell proliferation assay 125
- chaetocin 259
- ChIP DSL (DNA selection and ligation) 144
- ChIP sequencing (ChIP-Seq) 145
  - enriched region 146
- ChIP-chop 145
- chlamydocin 208ff.
- chromatin 139f., 267
- chromatin immunoprecipitation (ChIP) 139ff.
  - antibody 143
  - basic principle 141
  - ChIP-on-chip 144ff.
  - data analysis 146
  - data analysis example 149
  - variation 144
- CI-994 200
- cinnamic hydroxamic acid 194
- CoA-SH detection 107
- comperative molecular field analysis (CoMFA) 59
- comperative molecular similarity indices analysis (CoMSIA) 59
- CoREST target gene 271
- COX2 (cyclooxygenase-2) gene 175
- CRA-24781 197
- CTPB 244
- curcumin 245
- cutaneous T-cell lymphoma (CTCL) 185, 210
- cyclic hydroxamic acid-containing peptide (CHAP) 212
  - CHAP1 212
  - CHAP31 213
- cyclin 126
- cyclin dependent kinase (CDK)
  - inhibitor 228
- d**
- deacetylase
  - NAD<sup>+</sup> dependent 225ff.
- decitabine (dacogen) 170f.
- deleted in breast cancer 1 (DBC1) 233
- 2'-deoxy-5-fluorocytidine 170f.
- depsipeptide 189, 208
- diabetes type 2
  - SIRT1 as therapeutic target 231
- 7-diethylamino-3-(4'-maleimidylphenyl)-4-methylcoumarin (CPM) 108
- dihydrazalazine 173
- 1,5-diphenyl-1,4-pentadien-3-one 75
- disease
  - DNA methylation 169
- DNA fragmentation 143
- DNA methyl-binding protein (MBD1) 5
- DNA methylation 3ff., 163
  - aberrant 13
  - biochemical mechanism 168
  - disease 169
  - physiological role 168
- DNA methyltransferase (DNMT) 3ff., 46, 61, 165ff.
  - *de novo* 4
  - maintenance 4
- DNA methyltransferase (DNMT) inhibitor 13, 170ff.
- covalent 170ff.
- Dnmt1 46
- DNMT1 4, 14, 61, 165ff.
- DNMT2 165f.
- Dnmt3 46
- Dnmt3L 46
- DNMT3-like (DNMT3L) 4, 165f.
- Dnmt3a 46
- DNMT3A 4, 165f.
- Dnmt3b 46
- DNMT3B 4, 165f.
- noncovalent 173f.

- therapeutic application 175
- DNA organisation 139
- DNA repair 169
- docking program 59
- ligand docking 59
- DOT1 255
- drug discovery
  - cell-based assay for HDAC inhibitor hit validation 119ff.
  - computer-based 58ff.
  - pharmacophore-based 58f.
  - high-throughput screening (HTS) 99

## e

- E-cadherin 130
- ELAND (efficient large-scale alignment of nucleotide database) algorithm 147
- electron capture dissection (ECD) 92
- electron transfer dissociation (ETD) 94
- electrophilic ketone 206
- enriched region
  - analysis 148
  - annotation 148
  - detection and definition 146
- (–)-epigallocatechin-3-gallate (EGCG) 174
- epigenetic modification 3ff.
  - ChIP-Seq data analysis 153
- epigenetic target
  - computer- and structure-based lead identification 57ff.
  - structural biology 23
- ER-binding motif (ERE family) 153
- estrogen receptor (ER)
  - ChIP data analysis 149
- euchromatin 6
- EX-527 228
- EZH2 259

## f

- FAHA (2-furylacryloylhydroxamate) 106
- fatty acid
  - short-chain 188
- FB188 HDAH (histone deacetylase-like amidohydrolase from *Bordetella/Alcaligenes* strain FB188) 30ff.
- FBXL10/JHDM1B/KDM2B 271ff.
- FBXL11/JHDM1A/KDM2A 271ff.
- FK228 124, 189, 208
- flavine adenine dinucleotide (FAD) 111
- flow cytometry analysis (FACS) 127f.
- Fluor-de-Lys 120, 132
- fluorescence polarization (FP) 106
- fluorescent assay 102ff.
- 5-fluorocytosine 170

- 5-fluoroorotic acid (5-FOA) 126
- Fourier transform mass spectrometer (FTMS) 92
- FOXO3a 233
- FR225497 211
- FR235222 211
- FR-901228, *see* romidepsin
- FRM1 235

## g

- G9a, *see* lysine methyltransferase
- GAR motif 250
- garcinol 245
- Gcn5 27
- gene expression analysis
  - high-throughput 126
- genistein 174
- genome tiling array 144
- GNAT (Gcn5-related *N*-acetyltransferase) family 24, 73, 242
  - structure 24f.
- GOLD program 68
- GRID/GOLPE program (generating optimal linear PLS estimation) 59
- guttiferone G 228

## h

- H2BK120 12
- HC-toxin 208ff.
- HDASH method 102
- hDOT1L 255
- heat shock protein Hsp90 124ff.
- heterochromatin 6
- heterochromatin protein 1 (HP1) 7f.
- heterocyclic hydroxamic acid 198
  - SAR 199
- hexamethylene bisacetamide (HMBA) 190
- high performance capillary electrophoresis (HPCE) 88
- high performance liquid chromatography (HPLC) 88
- high-throughput assay
  - *in vitro* 121
- high-throughput gene expression analysis 126
- high-throughput screening (HTS) 99
- histacin 206
- histone 88
  - detection of acetylation 123
  - H3 245, 268ff.
  - H3K4 8ff., 267ff.
  - H3K4me3 268
  - H3K4me3/me2 279
  - H3K9 272

- H3K9me2/me3 267
  - H3K27me2/me3 267
  - H3K36 11, 267ff.
  - H3K79 267
  - H3R2 11
  - H3R2me2 268
  - H4 230, 245
  - H4K20me3 267
  - histone acetyltransferase (HAT) 6, 24, 73, 107
    - catalytic mechanism 29
    - clinical study 105
    - inhibitor (HATi) 243ff.
    - radioactive assay 107
    - structure 24ff.
    - substrate 242
  - histone arginine demethylase 45
  - histone arginine methyltransferase 39
  - histone code 87, 268
    - hypothesis 5, 139
  - histone binding domain (HBD) 7
  - histone deacetylase (HDAC) 6ff., 29f., 62, 101, 119
    - activity assay in cultured cell 123
    - aminoaniline 204
    - assay 101ff.
    - binding of acetylated lysine 32
    - catalytic mechanism 32f.
    - cell-based assay 122
    - classic 62
    - classification 30, 119, 186
    - clinical study 104
    - effect of SAHA on individual isoforms 122
    - HDAC4 33
    - HDAC6 64, 103, 128, 206, 230
    - HDAC7 48, 128
    - HDAC8 30ff., 103, 186
    - isoform functional assay 128
    - mechanism 186
    - NAD<sup>+</sup> dependent 228ff.
    - SAR exploration of HDAC1 and HDAC2-selective aminoaniline 205
    - structural basis of inhibition 33
    - structure 30
    - substrate 242
    - therapeutic target 225ff.
    - X-ray crystal structure 186
  - histone deacetylase (HDAC) inhibitor (HDACi) 13ff., 66, 100ff., 185ff.
    - cell-based assay 119
    - HDAC6 inhibitor 215
    - *in vitro* assay 120
    - pharmacophore 189
    - SAR 193ff.
    - thiol 213
  - histone deacetylase-like protein (HDLP) 30, 62ff.,
  - histone demethylase (HDM) 6, 39, 78, 111, 267ff.
  - histone demethylation 252, 268
    - mechanism by LSD1 catalysis 270
  - histone demethylation 44
  - histone lysine (K) methyltransferase (HKMT) 36
    - SET domain 36
  - histone methylation 268
    - enzyme 35
  - histone methyltransferase (HMT) 6, 74, 110, 252
    - cancer 268
    - drug target 249ff.
    - inhibitor 255
  - histone modification 5
    - analysis 87ff.
    - cross-talk 11
  - histone-modifying enzyme
    - *in vitro* assay 99ff.
  - homology model 63
  - HOX gene 13
  - HR73 228
  - Huntington disease (HD) 234
  - hybrid cyclic tetrapeptide 212
  - hydralazine 14, 173
  - hydroxamate 121
  - hydroxamic acid 190ff.
    - heterocyclic 198
  - N-hydroxyphenyl-2-propenamide 194
  - hyperforin 228, 246
- i**
- in vitro* assay 99ff.
  - in vitro* high-throughput assay 121
  - in vitro* isoform-specificity assay 121
  - indole-based inhibitor 72
  - inhibition of HDAC 33, 66
    - structural basis
  - inhibitor of growth 2 (ING2) 9
  - insulin receptor substrate 2 (IRS-2) 235
  - insulin-like growth factor 1 (IGF-1) 235
  - insulin-like growth factor binding protein 1 (IGFBP1) 235
  - invasion assay 130
  - isonicotinamide 231
  - ITF2357 198
- j**
- JARID1/KDM5 43, 278
    - JARID1A/KDM5A/RBP2 278f.
    - JARID1B/PLU-1/KDM5B 271ff.

- JARID1C/SMCX/KDM5C 271ff.
- JARID1D/SMCY/KDM5D 278ff.
- JARID2 (jumonji protein) 274
- JASPAR 153
- JFD00244 68
- JmjC
  - clinical study 105
- JmjC containing histone demethylase (JHDM) 43, 274
  - inhibitor 280
  - JHDM1 (KDM2) 43, 270ff.
  - JHDM2 (KDM3) 43, 277
  - JHDM3/JMJD2 (KDM4) 43, 276ff.
- JmjC family (Jmj C domain containing protein) 42, 78, 112, 274f.
- JmjC hydroxylase 7
- JMJD1/KDM3 277
  - JMJD1A/TSGA/JHDM2A/KDM3A 277
  - JMJD1B/JHDM2B/KDM3B 277
  - JMJD1C/TRIP8/JHDM3C/KDM3C 277
- JMJD2/KDM4 43, 278
  - JMJD2A/JHDM3A/KDM4A 271ff.
  - JMJD2B/JHDM3B/KDM4B 271ff.
  - JMJD2C/GASC1/JHDM3C/KDM4C 271ff.
- JMJD2D/JHDM3D/KDM4D 278
- JMJD2E 281
- JMJD3/KDM6B 43, 280
- JMJD6 45, 252
- JNJ-16242299 198
- Jumonji C (JmjC) domain 41, 252, 274

## k

- KD5170 216
- KDM, *see* lysine histone demethylase or JmjC containing histone demethylase
- ketone
  - aliphatic 213
  - electrophilic 206
- kinase inhibitor 228
- KMT, *see* lysine methyltransferase
- knockout animal model
  - HDAC isoform 129

## l

- lactam-based inhibitor 71
- lead identification 57ff.
  - computer- and structure-based 57ff.
- ligand docking 59
- ITK-14 246
- luminescent oxygen channelling immunoassay (LOCI) 108
- lysine demethylase 111
  - JHDM1 (KDM2) 43

- lysine histone demethylase (KDM) 41
  - KDM1 41
- lysine methylation 251
- lysine methyltransferase (KMT, PKMT) 36, 110, 252ff.
  - cancer 253
  - G9a 76ff., 250ff.
  - inhibitor 258f.
- lysine-specific histone demethylase (LSD1, AOF2, BHC110, KDM1, p100b) 41, 78, 111f., 252, 269ff.
  - clinical study 105
  - inhibitor 272
  - mechanism for demethylation by LSD1 270
  - potential drug target 271

## m

- MAL (Boc(Ac)Lys-AMC) 102
- mass spectrometry 89ff.
  - histone modification analysis 87
- MB-3 244
- MC1626 245
- MC1752 245
- MC1823 245
- MeCP2 (methyl CpG binding protein 2) 125
- MEF 125
- MEK/ERK1/2 235
- metabolic syndrome
  - SIRT1 as therapeutic target 231
- methyl-CpG-binding domain protein (MBD) 164ff.
- methyl-DNA immunoprecipitation (MeDIP) 146
- MGCD0103 200ff.
- MGMT (methyl guanine methyl transferase) 174
- microarray/promoter tiling array 144
- microRNA (miRNA) expression 169
- mithramycin A 174
- mixed lineage leukemia (MLL) 254
- MS-275 16, 121ff., 189, 200ff.
- mSin3A 130
- myelodysplastic syndrome (MDS) 175
- MYST (MOZ, Ybf2/Sas3, Sas2, Tip60) family 24, 74, 242
  - structure 26

## n

- NAD<sup>+</sup> 66f., 226ff.
- native ChIP (N-ChIP) 142
- neurological disease 234
- NF675 72
- nicotinamide 229

- nicotinamide mononucleotide
  - adenylyltransferase (Nmnat1) 234
- nonhistone protein 123
- nonSET domain lysine methyltransferase 249
- NSC303530 173
- NSC401077 173
- nucleosome code 251
- NVP-LAK974 194
- NVP-LAQ824 195ff.
- o**
  - oncogenesis modulator protein 126
  - oncoprotein 233
  - oxalglycine 281
  - oxamflatin 191
- p**
  - p16<sup>INK4</sup>* 174
  - p21 124ff., 191ff.
  - p53 124ff., 233, 243, 251
  - p300 26ff., 243ff.
  - p300/CBP family 74, 242
  - PAD, *see* peptidyl arginine deiminase or protein arginine deiminase
  - panobinostat 194
  - pargyline 272
  - Parkinson's disease 234
  - paullone 228
  - PCAF (p300/CBP-associated factor)
    - inhibitor 109, 243ff.
  - PCI-24781 197
  - PCI-34051 197
  - peripheral T-cell lymphoma (PTCL) 210
  - peptidyl arginine deiminase (PAD) 44
    - PAD14/PAD4 45, 252
  - PGC-1alpha 234
  - PGM motif 251
  - pharmacophore descriptor 58
  - phenyl hydroxamic acid 197
  - 4-phenylimidazole derivative 15
  - β-phenylsplitomicin (R)-8c 71
  - phloroglucinol derivative 228, 246
  - pivanex 189
  - PKMT, *see also* lysine methyltransferase
    - clinical study 105
  - plant homeodomain (PHD) finger 8f.
  - posttranslational modification (PTM) 87
  - procainamide 173
  - procaine 14, 173
  - protein arginine deiminase (PAD) 7
  - protein arginine methyltransferase (PRMT)
    - 7, 36ff., 110, 249ff.
    - binding protein 251
    - classification 252
    - clinical study 105
    - disease 250
    - inhibitor (AMI) 255
    - PRMT1 39, 74ff., 254
    - PRMT3 39, 74
    - PRMT4 (CARM1) 39, 48, 75, 250ff.
    - PRMT5 254
    - PRMT6 11, 39
  - protein methylation 249
  - proton transfer reaction (PTR) 94
  - psammaplin A 173f., 211
  - psammaplin F 211
  - PWWP domain 4
  - PXD-101 196
  - 2,4-pyridine dicarboxylic acid 281
- q**
  - 3D quantitative structure–activity relationship (3D-QSAR) 59
  - study 64
- r**
  - R306465 198
  - radioactive HDAC assay 101
  - RAG2-PHD finger 9f.
  - RAS/ERK1/2 signaling 235
  - Re-ChIP 145
  - reporter system 125
  - resveratrol 230
  - reversed phase chromatography 89
  - RG108 14, 173
  - RM-65 76, 256
  - RMAP algorithm 147
  - Ro-318220 67
  - romidepsin 189, 208
  - Rpd3S HDAC complex 11
  - Rubinstein–Taybi syndrome (RTS) 241
  - Rtt109 26ff.
- s**
  - SAHA, *see* suberoyl anilide hydroxamic acid
  - SAM (statistical testing algorithm), *see also* S-adenosyl-L-methionine 146
  - SB-379 278-A 121
  - scoring function 59
  - screening
    - hierarchy 99
    - histone modifying enzyme 100
  - sequence-specific DNA binding protein 125
  - SET domain
    - HKMT 36
  - SET domain lysine methyltransferase 249
  - SET family 7

SET7/9 255f.  
 signal transduction 169  
 silent information regulator (SIR) 225  
 sin3A 125  
 sinefungin 255  
 Sir2 225ff.  
 SIRT2 225ff.  
 SIRT1 226ff.  
   – therapeutic target 231  
 Sirt2 67ff.  
 SIRT2 226ff.  
   – inhibitor 70  
 SIRT6 226f.  
 sirtinol 228  
 sirtuin family, *see also* silent information  
   regulator 30ff., 66, 226ff.  
   – activator 230f.  
   – catalytic mechanism 35  
   – enzymatic activity 226  
   – modulation by endogenous molecules 226  
   – small molecule inhibitor 228f.  
   – structure 34  
 SMART 125  
 SNDX-275 189, 200ff.  
 sodium butyrate 124  
 spiruchostatin A and B 210  
 splitomicin 228  
 statistical testing algorithm 146  
 stilbamidine 75, 257  
 STR1720 231  
 suberoyl anilide hydroxamic acid (SAHA,  
   vorinostat, zolinza) 15, 33, 107, 124ff., 189  
   – HDAC isoform 122  
 suberoyl bishydroxamic acid (SABA) 190  
 substrate specificity 120  
 sulphur-containing cyclic peptide  
   (SCOP) 213  
   – SCOP31 213  
 suramin 72, 228  
 Suv39H1 255ff.  
 Suv39H2 255  
 SWI/SNF complex 8  
 SXOligoSearch algorithm 147

## t

T-test 146  
 TAF1 (formerly TAF<sub>II</sub>250) 10  
 TAF3-PHD finger 12  
 target gene

  – depletion in cells 128  
 tenovin-6 229  
 therapeutic target  
   – NAD<sup>+</sup> dependent deacetylase 225ff.  
 thiobarbiturate 71  
 thiol 213ff.  
 thiophen-2-yl hydroxamic acid 198  
 TIMP3 175  
 Tip60 243  
 top-down proteomics 92  
 transcription factor (TF) 148  
   – specific ChIP 149  
 transcription factor binding site (TFBS) 148  
 TRANSFAC 153  
 tranlycypromine 272  
 trapoxin 16, 124  
 trapoxin A 208ff.  
 trapoxin B 124, 210  
 trichostatin A (TSA) 15, 33, 124ff., 190  
 tubacin 121, 206  
 $\alpha$ -tubulin 124ff.  
 tubulin deacetylase (TDAC) 121, 206, 230  
 Tudor domain 251  
 tumor growth inhibition (TGI) 194  
 tumor suppressor 126  
   – gene (TSG) 233  
 tumor xenograft model 130

## u

UTX/JMJD3 (KDM6A) 13, 280  
 UTY 280

## v

valproic acid 15, 188  
 VEGF (vascular endothelial growth  
   factor) 126ff.  
 virtual screening (VS) 60  
   – study 64  
 VOLSURF program 68  
 vorinostat, *see* suberoyl anilide hydroxamic acid

## x

X-ChIP 142

## z

zebularine 14, 170ff.  
 ZMAL (Z(Ac)Lys-AMC) 103  
 ZML 103  
 zolinza, *see* suberoyl anilide hydroxamic acid

